ISSN: 2642-6145
Authors: Yesmin MS*1, Sultana A2 and Bashir MS3
Breast cancer is the leading cause of cancer-related death among females. The current study is one of the initial studies to evaluate the diagnostic value of novel serum MACC-1 markers in breast cancer patients. Various other serum biomarkers have been used for the diagnosis of breast cancer but this marker proved a good sensitivity and/or specificity. This cross-sectional study included 32 breast cancer patients and 32 normal healthy controls. Study subjects demographic, pathologic, and clinical information were recorded. Random blood samples were collected from the antecubital vein after aseptic precaution with 0.5% chlorhexidine gluconate. About 4.0 ml of venous blood was collected into a red screw-capped tube. Serum MACC-1 was assessed by a double-antibody sandwich ELISA method by using the commercially available kit in the Department of Laboratory Medicine, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. In this study, serum MACC-1 levels were significantly elevated (p< 0.0001) in breast cancer patients compared to the control group. The mean serum MACC1 was elevated in BC patients (55.21 ± 14.75 pg/ml) compared with healthy controls (38.19 ± 11.42 pg/ml) (P<0.0001). The median age was 46.3 years in BC patients and 40.2 ± 8.4 years in the control group (p <0.0001). Higher serum MACC1 levels were observed with increasing TNM stages (p < 0.0001). Therefore, this study showed that serum MACC-1 can be a potential biomarker for the diagnosis of breast cancer.
Keywords: Serum MACC-1 & T Stage; Breast Cancer; Carcinoembryonic Antigen; Serum Biomarker; Tumor Progression
